Ocrevus (Ocrelizumab)

Ocrelizumab is a humanized monoclonal antibody that binds to the CD20 protein on B‑cells, leading to their depletion through immune‑mediated mechanisms, which reduces the autoimmune activity that contributes to multiple sclerosis.

The dosing regimen for Ocrevus is determined by the prescribing physician based on the patient’s condition, weight, and clinical guidelines. Specific dose and infusion schedule are set by the treating healthcare professional.

Safety of ocrelizumab in pregnancy or while breastfeeding has not been fully established. Women who are pregnant, planning to become pregnant, or nursing should discuss potential risks and benefits with their healthcare provider.

To order Ocrevus, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Ocrevus is a CD20‑targeting monoclonal antibody, distinct from interferon‑based or oral disease‑modifying therapies. It offers the advantage of treating both relapsing and primary progressive forms of multiple sclerosis, whereas many alternatives are limited to relapsing disease only.

Ocrevus must be stored at 2‑8 °C (refrigerated), protected from light, and should not be frozen or shaken. It should be kept in its original packaging until ready for preparation and infusion.

Ocrevus is given as an intravenous infusion. The initial dose is split into two infusions administered two weeks apart, followed by a single infusion every six months, as directed by the treating physician.

Serious risks include opportunistic infections such as herpesvirus reactivation, potential development of malignancies, progressive multifocal leukoencephalopathy (PML), hepatitis B reactivation, and severe infusion reactions including anaphylaxis.

Patients with active infections, known hypersensitivity to ocrelizumab or any of its excipients, and those who are pregnant or breastfeeding without a clear risk‑benefit assessment should avoid using Ocrevus. Final eligibility is determined by the prescribing clinician.